文献速递头颈与中枢神经肿瘤

STELLAR:依氟鸟氨酸联合洛莫司汀对比洛莫司汀单药治疗复发性3级星形细胞瘤的III期随机开放标签研究

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
PubMed 文献 · J Clin Oncol · 2025-12-01

STELLAR是一项III期随机开放标签试验,比较依氟鸟氨酸联合洛莫司汀与洛莫司汀单药治疗复发性3级星形细胞瘤。343例患者随机入组,总生存无差异(中位OS 23.4 vs 20.3个月,HR 0.94)。在IDH突变型3级星形细胞瘤亚组(n=196)中,联合组中位OS(34.9 vs 23.5个月,HR 0.64)和中位PFS(15.8 vs 7.2个月,HR 0.57)有临床意义改善;4级肿瘤中未见差异。

要点

  • 联合组与单药组总体OS无显著差异(HR 0.94)。
  • IDH突变型3级亚组联合组PFS和OS均显著改善。
  • 4级肿瘤患者中未观察到联合治疗获益。

核心结论

  • 在复发性IDH突变型3级星形细胞瘤患者中,依氟鸟氨酸联合洛莫司汀较洛莫司汀单药双倍延长PFS并改善OS。
  • 在总体人群中未观察到生存差异,4级肿瘤患者中亦无差异。

研究设计与样本

  • III期随机开放标签试验(STELLAR,NCT02796261),343例患者来自8个国家74个中心,1:1随机分层因素包括IDH突变、年龄、切除范围和地域。
  • 入组标准包括年龄≥18岁、间变性星形细胞瘤(2016 WHO CNS4)、放疗和替莫唑胺后首次复发≥6个月、KPS≥70、无胶质母细胞瘤影像学证据。
  • 联合组接受依氟鸟氨酸(2.8 g/m2口服,每8小时一次,用2周停1周)联合洛莫司汀(90 mg/m2口服,每6周一次);单药组洛莫司汀110 mg/m2每6周一次。
  • 主要终点为总生存期(OS)。

主要发现

  • 总体人群中联合组与单药组中位OS分别为23.4个月和20.3个月(HR 0.94)。
  • IDH突变型3级星形细胞瘤亚组(n=196)中,联合组中位OS为34.9个月 vs 23.5个月(HR 0.64),中位PFS为15.8个月 vs 7.2个月(HR 0.57)。
  • 4级肿瘤患者中未观察到联合治疗与单药治疗的差异。
  • ≥3级治疗中出现的不良事件包括可逆性骨髓抑制(联合组42% vs 单药组29%)和听力损害(24% vs 0%)。
  • 未发现新的安全性信号。

关键数值与推荐

  • IDH突变型3级星形细胞瘤亚组中位OS联合组34.9个月 vs 单药组23.5个月(HR 0.64)。
  • IDH突变型3级星形细胞瘤亚组中位PFS联合组15.8个月 vs 单药组7.2个月(HR 0.57)。
  • ≥3级骨髓抑制发生率联合组42% vs 单药组29%;听力损害24% vs 0%。

临床怎么用

  • 对于复发性IDH突变型3级星形细胞瘤患者,在既往放疗和替莫唑胺治疗后,可考虑依氟鸟氨酸联合洛莫司汀方案。
  • 治疗期间需监测骨髓抑制和听力损害。
  • 4级肿瘤患者不推荐该联合方案。

局限性

  • 亚组分析基于2021 WHO CNS5分类和2024年定义的IDH突变型3级星形细胞瘤(n=196),为预先设定的亚组分析。
  • 开放标签设计可能引入偏倚。
  • 总体人群未达到主要终点,亚组结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS: At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase (IDH) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS: Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH-mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION: Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Colman H, Lombardi G, Wong ET, et al. STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. J Clin Oncol. 2025. PMID: 41325560. doi:10.1200/JCO-25-01204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。